Xspray Pharma Q3 2023: Approaching Commercialization - Redeye

Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises. We continue to observe a disconnect between operational newsflow and the share price as Xspray proceeds toward FDA approval and the anticipated Q3 2024 launch of Dasynoc.

Länk till analysen i sin helhet: https://www.redeye.se/research/956920/xspray-pharma-q3-2023-approaching-commercialization?utm_source=finwire&utm_medium=RSS